# Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta

> **NCT01417091** · PHASE2 · COMPLETED · sponsor: **Ultragenyx Pharmaceutical Inc** · enrollment: 10 (actual)

## Conditions studied

- Osteogenesis Imperfecta

## Interventions

- **DRUG:** BPS804

## Key facts

- **NCT ID:** NCT01417091
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01417091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01417091, "Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01417091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*